Newsroom

CHESTERFIELD, United Kingdom, Oct. 26, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, will report fourth quarter and full-year fiscal 2015 earnings results on Monday, Nov. 23, 2015, and will hold an investor briefing on Monday, Dec. 7, 2015, in New York City.

Earnings Call
For the Nov. 23 earnings report, a conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed in three ways:

• At the Mallinckrodt website: http://www.mallinckrodt.com/investors.
• By telephone: For both listen-only participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is (877) 359-9508. For participants outside the U.S., the dial-in number is (224) 357-2393. Callers will need to provide the Conference ID of 63820670.
• Through an audio replay: A replay of the call will be available beginning at 11:30 a.m. Eastern Time on Monday, Nov. 23, 2015, and ending at 11:59 p.m. Eastern Time on Monday, Dec. 7, 2015. Dial-in numbers for U.S.-based participants are (855) 859-2056 or (800) 585-8367. Participants outside the U.S. should use the replay dial-in number of (404) 537-3406. All callers will be required to provide the Conference ID of 63820670.

Investor Briefing
The Dec. 7 investor briefing will take place at The St. Regis New York, Two E. 55th St., New York, NY 10022, in the St. Regis Roof room on the hotel's 20^th floor. The agenda for the event follows; all times shown are Eastern Time.

Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt's senior management team. Attendees should register by emailing investor.relations@mallinckrodt.com.

Those unable to attend the briefing in person can listen to a live webcast at Mallinckrodt's Investor Relations website: www.mallinckrodt.com/investors. Please note the poster and products session will not be webcast. Following the end of the briefing, the presentation replay and materials will be available on the Mallinckrodt Investor Relations website.

ABOUT MALLINCKRODT
Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Contacts: 

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com

Media
Rhonda Sciarra
Senior Manager, Communications
314-654-8618
rhonda.sciarra@mallinckrodt.com

Meredith Fischer
Senior Vice President, Communications and Public Affairs
314-654-3318
meredith.fischer@mallinckrodt.com

Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-fourth-quarter-and-full-year-fiscal-2015-results-nov-23-2015-investor-briefing-planned-on-dec-7-2015-300166291.html

SOURCE Mallinckrodt plc